Document:

ADVISORY AGREEMENT

This Agreement is dated effective as of March 27, 2018

By and between:

 Ravi Vaidyanathan, an individual residing at 104 Bridge St, Oxford, OX2 0BD (the "Advisor")

And:

HCi Viocare, a Nevada corporation having a business office at Kintyre House, 209 Govan Road, Glasgow, Scotland, UK, G51 1 HJ (the "Company")

Whereas:

A. The Company has determined to establish a scientific advisory board and to appoint certain advisors who can contribute to the Company's overall business strategy and future direction.

B. The Advisor has certain business expertise and has agreed to provide advice and recommendations regarding the Company's overall business strategy and future direction.

Now therefore this Agreement witnesses that in consideration of the mutual covenants and agreements herein contained the parties hereto agree as follows:

Section 1. Interpretation

1.1 Where used herein the following terms shall have the meanings set out below:

(a) "Advisory Board" means the group of individuals appointed by the Company to act as advisors to the Board;

(b) "Advisory Services" means the advisory services to be provided by the Advisor to the Company as set out herein;

(c) "Board" means the board of directors of the Company;

(d) "Business Material" means any financial, market and technical information, methods and plans, trade secrets, know-how, technical expertise and other information relating to the Company's business and operations;

(e) "Term" has the meaning given to it in subsection 2.1.

1.2 Governing Law. 

This Agreement shall be governed by and be construed in accordance with the laws of Nevada applicable therein.

1.3 Severability. 

If any one or more of the provisions contained in this Agreement should be determined to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

1

Section 2. Term

2.1 Term. 

The term of this Agreement (the "Term") shall be from and including March 27 2018 to and including March 26 2019, unless this Agreement is earlier terminated in accordance with Section 5.

Section 3. Advisory Services

3.1 Advisory Services. 

The Company hereby appoints and retains the Advisor, on a non-exclusive basis, during the Term to serve as a member of the Advisory Board at the position of Biomechatronics and Human Augmentation Advisor and provide the Advisory Services as requested by the Company from time to time, and the Advisor hereby accepts such appointment to the Advisory Council and agrees to provide diligently the Advisory Services. In providing the Advisory Services, the Advisor will have an advisory role only and report directly to and take direction from the Board. In no circumstances will the Advisor perform any functions of the Board. The Advisor, as a member of the Advisory Board, shall attend as may be required by the Board, such meetings of the Advisory Board, either telephonically or in person, and provide Advisory Services to the Board which shall include:

(a) making recommendations for both the short term and the long-term business strategies to be employed by Company;

(b) monitoring and assessing the market for the Company's business and to advise the Board with respect to such markets and to recommend an appropriate business strategy on an ongoing basis;

(c) commenting on proposed corporate decisions and identifying and evaluating alternative courses of action;

(d) critiquing the managements' and directors' actions and making suggestions to strengthen the management structures, processes and operations;

(e) providing an objective evaluation of the performance of the Company and its management in relation to competitors within the industry;

(f) identifying and evaluating external threats and opportunities to the Company;

(g) evaluating and making ongoing recommendations to the Board with respect to the required management personnel and job functions for the efficient operation of the Company's business;

(h) formulating and recommending to the Board appropriate operating policies and procedures and supervising the implementation of such policies and procedures for the ongoing conduct of the Company's business;

(i) discussing from time to time any matters pertaining to the Company's business; and

(j) providing such other advisory or consulting services as may be appropriate from time to time.

3.2 Board to Act Independently. 

The Board shall diligently and responsibly receive all advice from the Advisor and the Advisory Board and exercise its own independent judgment before acting upon such advice.

3.3 Remuneration. 

(a)  In consideration of the provision of the Advisory Services, the Company shall grant the Advisor 500,000 shares of the Company's Common Stock to be issued upon signing of this Agreement.

2

(b) Further to the term 3.3 (a) above, and provided that the Agreement is not earlier terminated for any reason whatsoever, the Company shall grant the Advisory an additional 250,000 shares of the Company's Common Stock to be issued after a time-period of six (6) months from the signing of this Agreement.

(c) The Company shall further pay to the Advisor any out of pocket expenses which shall be prior approved by the Company for the attendance at any meetings of the Advisory Board.

3.4 Other Contractual Agreements

The parties to this Agreement recognize that they may enter into other contractual agreements for services to be provided to the Company for which independent contracts shall be executed and that this Agreement relates solely to the appointment of the Advisor to the Advisory Board and the mandate of the Advisory Board as noted by the Company and the Board.

3.5 Disclosure of Advisor.  During the Term, the Advisor shall:

(a) disclose to the Company all of its interests in any transaction or agreement contemplated by the Company or any matter which may taint the Advisor's objectivity when performing its role as an Advisor hereunder;

(b) inform the Company of any business opportunities made available to the Advisor as a result of the Advisor's involvement with the Company or otherwise through the performance of the Advisory Services; and

(c) inform the Company if asked to be an advisor, or consent to an appointment as a member of the board of directors, of a company which competes, directly or indirectly, with the Company. Written notification will be given at least thirty-five (35) days prior to accepting any such appointment, provided that such appointment is not violating the terms of this Agreement and any other contractual obligations.

Section 4. Confidential Information

4.1 Confidentiality Obligation. 

The Advisor recognizes and agrees that any Business Material furnished or to be furnished to it by the Company is to be used only for the purpose of providing the Advisory Services hereunder and that such Business Material will be kept confidential by the Advisor provided, however, that any such Business Material may be disclosed:

(a) if specifically consented to in writing by the Company; or

(b) if required by applicable law or by an order of a court of competent jurisdiction.

4.2 Exceptions. 

The provisions of Section 4.1 shall not apply to:

(a) information which becomes generally available to the public other than as a result of a disclosure by the Advisor;

(b) information which is generally known to knowledgeable business people involved in the business conducted by the Company other than as a result of a disclosure by the Advisor in violation of this part;

(c) information that was available to the Advisor on a non-confidential basis prior to its disclosure to the Advisor by the Company; or

(d) information that becomes available to the Advisor on a non-confidential basis from a person or entity other than the Company, unless such disclosure by that person is itself in breach of a confidentiality commitment made directly or indirectly to the Company;

and provided that nothing in this Agreement shall prevent the Advisor from using its expertise and knowledge in the conduct of other business for its own account or as a consultant to others.

3

5. Termination

5.1 Termination by the Company and the Advisor. 

The Company or the Advisor may terminate this Agreement without cause at any time by giving thirty (30) days written notice of termination of this Agreement to the other party. Any termination of this Agreement, either pursuant to this Section or otherwise, will not affect the obligations under Section 4, which will survive such termination. In the event that this Agreement is terminated by the Company, the Company shall pay the Advisor an amount equal to any expenses incurred by the Advisor up to the effective date of the termination to the extent such expenses have not previously been reimbursed. Upon payment of such amounts, the Advisor shall have no claim against the Company for damages or otherwise by reason of such termination. In the event of termination of this Agreement, the Advisor shall, prior to the effective date of the termination, deliver to the Company all books, records, or other information in its possession pertaining to the Company's business.

6. Indemnity and Limitation of Liability

6.1 Indemnification by the Company.

The Company shall indemnify and hold harmless the Advisor against any and all losses, damages, suits, judgments, costs and expenses arising under any such third party claim or action provided however, that the Advisor provides the Company with:

(a) written notice of such claim or action within 14 days of acquiring knowledge of the event;

(b) sole control and authority of the defense or settlement of such claim or action (provided that the Company shall not enter into any settlement which materially affects the Advisor's rights without the Advisor's prior written consent); and

(c) proper and full information and reasonable assistance to defend and/or settle any such claim or action.

6.2 No Liability for Acts of the Company. 

The Advisor shall not be liable for any act of the Company or any of its directors, officers or employees.

6.3 Limitation of Liability.

Under no circumstances will either party be liable to the other party for indirect, incidental, consequential, special or exemplary or punitive damages (even if such party has been advised of the possibility of such damages), arising from any provision of this Agreement, such as, but not limited to, loss of revenue or anticipated profits or loss of business.

7. General Provisions

7.1 No Partnership or Agency. 

The relationship between the Company and the Advisor is that of independent contractor and nothing herein contained shall be interpreted so as to create a partnership or agency relationship between the parties.

7.2 Assignment. 

Neither party may assign any rights or delegate any obligations hereunder without the prior written consent of the other party.

4

As evidence of their agreement this Agreement has been executed by the parties hereto as of the date first above written.

/s/Sotirios Leontaritis

HCi Viocare

Sotirios Leontaritis

CEO

 

/s/Ravi Vaidyanathan

Ravi Vaidyanathan

 

 

5Blueprint

 

Exhibit 10.2

FIRST ADDENDUM

TO ASSET PURCHASE AGREEMENT AND EMPLOYMENT AGREEMENT

 

THIS
FIRST ADDENDUM TO THE ASSET PURCHASE AGREEMENT and EMPLOYMENT
AGREEMENT (the “First Addendum”) is made as of this
16th day
of February 2018 (the “Effective Date”) by GrowLife,
Inc., a Delaware corporation (the “Company”), and David
Reichwein, a Pennsylvania resident (“Employee”), GIP
International Ltd, a Hong Kong corporation and DPR International
LLC, a Pennsylvania limited liability corporation (collectively,
the "Seller"). Company, Seller and Employee are sometimes referred
to herein as the “Party” or, collectively, the
“Parties.”

 

RECITALS

 

WHEREAS, the Parties entered into an
Asset Purchase Agreement dated October 2, 2017 (the “Purchase
Agreement”), attached hereto as “Exhibit A” and
incorporated herein by reference, pursuant to which the Company
purchased 51% of the Assigned Intellectual Property and Purchased
Assets in exchange for the Purchase Price;

 

WHEREAS, the Parties entered into an
Employment Agreement dated October 1, 2017 (the “Employment
Agreement”) setting forth the compensation terms surrounding
Employees employment by the Company, attached hereto as
“Exhibit B” and incorporated herein by
reference;

 

WHEREAS, the Parties wish to formally
supplement the Purchase Agreement and Employment Agreement by this
First Addendum to purchase the remaining 49% ownership of the
Assigned Intellectual Property and Purchased Assets including the
FreeFit properties and related assets (“FreeFit”) as of
the date of this First Addendum; and

 

WHEREAS, capitalized terms used herein,
but not otherwise defined, shall have the meanings ascribed to such
terms in the Purchase Agreement and Employment
Agreement.

 

NOW THEREFORE, in consideration of the
foregoing recitals and the mutual covenants and representations
contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows:

 

 

AGREEMENT

 

1.

Recitals. The foregoing recitals are true and
correct in all material respects and are hereby incorporated herein
as a material part of this First Addendum.

 

2.

Addendum to the Purchase Agreement – Purchase of Remaining
49% interest.

 

As of
the Effective Date, the Seller hereby sells, assigns, transfers,
and sets over unto the Company the remaining 49% rights, title and
interest in and to the Intellectual Property and Purchased Assets
as defined in the Purchase Agreement (the “49%
Interest”), in exchange for a one-time payment of $250,000
made by Company to Seller (the “Additional Purchase
Price”). The purchase and sale of the 49% Interest is subject
to all terms, conditions, representations and warranties as set
forth in the Asset Purchase Agreement. Seller further warrants that
all representations and warranties set forth in the Asset Purchase
Agreement are true and correct as of the Effective Date and as
applied to the 49% Interest.

 

 

1

 

 

The
Parties agree that Section 3.4.A regarding the Compensation
Agreement and the 10% commission and any residual percentage
payments related to Free Fit is removed in its entirety and
replaced by the terms set forth in Section 3 herein.

 

As of
the Effective Date, Seller shall deliver a bill of sale in the form
of Exhibit C hereto (the "Bill of Sale") and duly executed by
Seller, transferring the 49% to Company and Company shall deliver
the Additional Purchase Price to Seller.

 

3.

Amendment to Section 1.b. of the
Employment Agreement. Section 1.b. currently
provides:

 

“b. Incentive
Compensation.

Starting on the first quarter (“Q1”)
you are eligible to earn a quarterly commission based on 10% of
tile gross margin dollars.”

 

 Section
1.b. of the Employment Agreement is hereby revoked, repealed, and
replaced in its entirety with the following:

 

“b. Incentive
Compensation.

i.

Cash Bonus. The Company will
make up to a maximum of two $100,000 payments to Employee for any
two quarters based upon meeting the following FreeFit revenue and
gross margin goals in 2018:

a.

Upon achievement of
a minimum of $900,000 paid-in FreeFit revenue and at 30% cash after
cost of goods (“gross margin”) or at least $270,000,
during the quarter ending March 31, 2018;

b.

Upon achievement of
a minimum of $1,000,000 paid-in FreeFit revenue and at 30% gross
margins or at least $300,000, during the quarter ending June 30,
2018;

c.

Upon achievement of
a minimum of $1,000,000 paid-in FreeFit revenue and at 30% gross
margins or at least $300,000, during the quarter ending September
30, 2018; or,

d.

Upon achievement of
a minimum of $1,000,000 paid-in FreeFit revenue and at 30% gross
margins or at least $300,000, during the quarter ending December
31, 2018, and;

ii.

Common Stock Bonus.

a.

Upon FreeFit
generating $2,000,000 of paid-in revenue and at 30%+ gross margins
or at least $600,000 from FreeFit no later than the quarter ending
September 30, 2018, Employee will receive an additional 5,000,000
restricted shares of common stock at the current market
price;

b.

Upon achieving
$1,000,000 of revenue and at 30%+ gross margins from new GrowLife
patent pending products in 2018, such as GrowLife Rooms, GrowLife
Nutrient System, etc. Employee will receive an additional 2,500,000
restricted shares of common stock at the current market
price.”

 

4.

Full Force and Effect of Other
Terms. The Parties
hereby confirm that all other terms and conditions of the Purchase
Agreement and Employment Agreement are in full force and effect and
are un-amended except as expressly provided in this First
Addendum.

 

5.

Counterparts. This First Addendum may be executed in
one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the
same agreement.

 

6.

Electronic
Signatures. The
Parties agree that any form of electronic signature, including but
not limited to signatures via facsimile, scanning, or electronic
mail, may substitute for the original signature and shall have the
same legal effect as the original signature.

 

SIGNATURE PAGE FOLLOWS

 

 

2

 

 

SIGNATURES

 

IN
WITNESS WHEREOF, the parties hereto have executed this THIS FIRST
ADDENDUM TO THE ASSET PURCHASE AGREEMENT and EMPLOYMENT AGREEMENT
on this 16th day of February,
2018.

 

 

GrowLife, Inc.

 

/s/ Marco Hegyi

Name: Marco Hegyi

Title: Chief Executive Officer

 

David Reichwein

 

/s/
David Reichwein

David Reichwein

 

GIP International Ltd

 

/s/
David Reichwein

David Reichwein

Its: Sole Shareholder

 

DPR International LLC

 

/s/
David Reichwein

David Reichwein

Its: Sole Shareholder

 

 

 

3

 

 

Exhibit A

 

“ASSET
PURCHASE AGREEMENT”

 

 

 

 

 

 

4

 

Exhibit B

 

“EMPLOYMENT
AGREEMENT”

 

 

 

 

 

5

 

Exhibit C

BILL OF
SALE

 

BILL OF SALE AND GENERAL ASSIGNMENT

 

February
16th ,
2018

 

For
good and valuable consideration, including consideration under the
First Addendum to that certain Asset Purchase Agreement dated
approximately the same date as this instrument (that agreement, the
“First
Addendum”), David Reichwein, a Pennsylvania resident,
GIP International Ltd, a Hong Kong corporation and DPR
International LLC, a Pennsylvania limited liability corporation
(collectively, the "Seller"), hereby sells and transfers the
remaining 49% Interest in the Assigned Intellectual Property and
Purchased Assets (as defined in the Purchase Agreement) to
Growlife, Inc., a Delaware corporation (the “Company”). This instrument is
subject to and construed in accordance with the Purchase Agreement
and First Addendum thereto.

 

On one
or more occasions after the date of this instrument, the Seller, at
the request of the Company,
shall execute and deliver further instruments of transfer and
assignment and take any other action as the Company may reasonably
require to more effectively transfer to the Company each of the
Assigned Intellectual Property and Purchased Assets and to assist
the Company in exercising all rights with respect to the Assigned
Intellectual Property and Purchased Assets.

 

The
Sellers are signing this Bill of Sale and General Assignment on the
date stated in the heading.

 

 

David Reichwein

 

/s/
David Reichwein

David
Reichwein

 

GIP International Ltd

 

/s/
David Reichwein

David
Reichwein

Its:
Sole Shareholder

 

DPR International LLC

 

/s/
David Reichwein

David
Reichwein

Its:
Sole Shareholder

 

 

 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]